From McKnight’s – An advisory committee to the U.S. Food and Drug Administration voted unanimously last week that the FDA should approve a brain scan that can identify the beta amyloid plaques that characterize Alzheimer’s in living persons. The FDA typically follows the advice of the advisory committee. Prior to...